Heart failure & cardiomyopathies
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Authors' conclusion
Among participants with T2DM, the WATCH-DM and TRS-HFDM can reliably identify those at high risk for HF hospitalization and most likely to benefit from canagliflozin.
Study context
- Population
- Participants with T2DM in the CANVAS trial, categorised into low, medium and high heart failure (HF) risk by WATCH-DM (without prevalent HF) and TRS-HFDM (all participants)1,446 (14.3%) with baseline HF
- Participants
- 10,137 participants
- Comparison
- Canagliflozin vs placebo across baseline HF risk strata
- Primary endpoint
- Time to first HF hospitalization
Methodological detailssubgroup analysis by baseline HF risk
- Subgroup analysis by baseline HF risk
Primary result
As reported in the abstract
HF hospitalization by baseline HF risk
Canagliflozin vs PlaceboHazard ratio (95% CI)P value
WATCH-DM high risk (no baseline HF): 8.1%vs 12.7%; NNT 22
0.62(0.37–0.93)
P = 0.03TRS-HFDM high risk: 39% risk reduction; NNT 20
0.61(0.48–0.78)
P < 0.001- WATCH-DM risk category did not modify the treatment effect (P interaction)
- 0.56
- TRS-HFDM: significant difference in treatment effect across risk strata (P interaction)
- 0.04
Original publication
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk. JACC Heart Fail. Published 24 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →